The regulation of mKNA encoding transforming growth factor 3 (TGF-/3) and interleukin 2 (I1,2) in normal human T cells was explored using novel competitor DNA constructs in the quantitative polymerase chain reaction and accessory cell-independent T cell activation models. Our experimental design revealed the following: (a) TGF-3 mRNA and IL-2 mRNA are regulated differentially in normal human T cells, quiescent or signaled with the synergistic combinations of: sn-l,2-dioctanoylglycerol and ionomycin or anti-CD3 monoclonal antibody (mAb) and anti-CD2 mAb; (b) the steady-state level of TGF-B mRNA in the stimulated T cells, in contrast to that of II.2 mRNA, is increased by the immunosuppressant cyclosporine (CsA); and (c) the paradoxical effect of CsA on TGF-3 mRNA levels is also appreciable at the level of production of functionally active TGF-3 protein. Our findings, in addition to demonstrating the utility of the competitor DNA constructs for the precise quantification of immunoregulatory cytokines, suggest a novel and unifying mechanistic basis for the immunosuppression and some of the complications (e.g., renal fibrosis) associated with CsA usage. T ransforming growth factor 3 (TGF-3), a 25-kD homodimeric multifunctional cytokine and a secretory product of many cell types including T cells, is a potent inhibitor of T cell growth and differentiation (1-3). I1,2, on the other hand, promotes T cell growth and their acquisition of specialized effector functions (4). TGF-B and I1,2, thus, have the potential to exert diametrically opposite effects on the expression of antigen-specific T cell immunity. It was of interest, therefore, to quantify, simultaneously, the regulation of mRNA encoding TGF-3 and Ib2 in normal human T cells. Also, in view of the ability of TGF-3 to inhibit the antiallograft response (5), it was considered important to quantify the effect of cyclosporine (CsA) on the induction of TGF-fl mKNA in normal human T cells, and compare it to its well-characterized inhibitory effect on the induction of II.-2 mRNA (6).
T ransforming growth factor 3 (TGF-3), a 25-kD homodimeric multifunctional cytokine and a secretory product of many cell types including T cells, is a potent inhibitor of T cell growth and differentiation (1) (2) (3) . I1,2, on the other hand, promotes T cell growth and their acquisition of specialized effector functions (4) . TGF-B and I1,2, thus, have the potential to exert diametrically opposite effects on the expression of antigen-specific T cell immunity. It was of interest, therefore, to quantify, simultaneously, the regulation of mRNA encoding TGF-3 and Ib2 in normal human T cells. Also, in view of the ability of TGF-3 to inhibit the antiallograft response (5) , it was considered important to quantify the effect of cyclosporine (CsA) on the induction of TGF-fl mKNA in normal human T cells, and compare it to its well-characterized inhibitory effect on the induction of II.-2 mRNA (6).
Materials and Methods
Isolation and Activation of T Cells. T cells were isolated from normal human PBMC with a sequential muhi-step procedure that yields >98% CD2 antigen-positive cells and <1% cells that are positive for the DR, CD14, CD25, or CD56 antigens (7) . Accessory cell-independent T cell activation was accomplished with either sn-l,2-dioctanoylglycerol (DAG; 10.0/zg/ml) and ionomycin (1.0 #M) or crosslinked anti-CD2 (OKT11; 0.5 #g/ml) and anti-CD3 (OKT3; 0.5 #g/ml) mAbs (7).
Design and Synthesis of Competitor DNA Constructs. Fig. 1 illustrates the design, synthesis, and authentication of the 290-bp TGF-/~ competitor DNA construct created for the quantification of TGF-B mRNA by PCR. As shown, the oligonucleotide primer pair was designed to amplify a region in the TGF-3 gene that contains a MseI restriction site. The MseI digestion of the 246-bp TGF-3 PCK product yielded 210-and 36-bp subfragments that were annealed with a 44-bp DNA insert synthesized in vitro to have cohesive ends for the MseI restriction site at 5' and 3' ends. The phosphorylated 44-bp DNA fragment was ligated with the 210-and 36-bp DNA fragments using Esckerichia coli DNA ligase. After ligation, the mixture was run on a 2% low melting point agarose gel, and the 290-bp fragment was eluted and purified using the gene dean kit.
The 178-bp I1-2 competitor DNA construct was created in a similar fashion. Here, the phosphorylated 44-bp DNA insert was ligated with the 88-and 46-bp subfragments derived by MseI digestion of the I1-2 PCR product.
Quantification by Competitive PCR. The cDNA, for quanti-fication by competitive PCIL (8) , was synthesized in a reverse transcription reaction mixture containing 1/~g of total RNA (isolated from normal human T cells by the guanidinium isothiocyanate/ cesium chloride method), 100 ng of random hexanucleotide primers, and 200 U ofmoloney routine leukemia virus reverse transcriptase. A constant amount of the cDNA (2/zl) was then coamplified with known concentrations of the competitor DNA construct, for 32 cycles using 200/~M TGF-3 or II:2 gene-specific primer pairs in a reaction mixture (50/A) containing lx Taq buffer, 1 U Taq DNA polymerase, and 40/~M of each dNTP. The PCR products were resolved by 2% agarose gel electrophoresis, visualized by ethidium bromide staining, and photographed. The negative of the photographs was analyzed by laser densitometry, and the absolute absorbance values of the PCR products were determined. The ratios of the absorbance of the relevant PCIL product pairs (290-bp TGF-~3 competitor and 246-bp TGF-3; 178-bp II-2 competitor and 149-bp Ib2 PCR product) were plotted against the concentration of the competitor DNA used. The concentration of mRNA was thus determined and expressed as attomoles (amol) of TGF-3 or IL-2 mRNA/mg of total RNA.
Results and Discussion
Differential Regulation of TGF-{3 mRNA and 11,2 raRNA.
The steady-state levels of TGF-3 mRNA and Ib2 mRNA in normal human T calls, quantified by competitive PCR, are displayed in Table 1 . Several features that distinguish TGF-3 mRNA regulation in T calls from that of Ib2 mRNA are apparent. First, in quiescent normal human T cells, TGF-fl mRNA is readily quantifiable at every time point tested, and Ib2 mRNA is not detectable, at any of the time points evaluated, even by the application of the sensitive PCR methodology (Table 1) . Second, quantitative and qualitative differences exist between TGF-/J mRNA and Ib2 mRNA regulation in T cells signaled with the synergistic combination of DAG and ionomycin. As shown in Table 1 , the concentration of Ib2 mRNA in the stimulated T cells is severalfold greater than that of TGF-fl mRNA in the same T cell population, and the highest concentration of Ib2 mKNA is found 4 h after stimulation, and that of TGF-f3 mKNA 1 h after signaling of T cells with DAG and ionomycin.
The most striking difference between TGF-B mRNA regulation and that of I1.-2 mKNA was evident when T cells, pretreated with CsA, were signaled with DAG and ionomycin. Whereas CsA completely prevented activation-dependent Ib2 mKNA accumulation in the T cells, the steady-state levels of TGF-fl mRNA were increased by CsA ( Table 1) . The Ca/kmediated increase in the abundance of TGF-3 mKNA was best seen at the 1 h time point (Table 1) . (Fig. 2, A3 and B3) . Thus, CsA increased the steady-state level of TGF-3 mRNA from 1,992 to 9,903 amol in T cells stimulated via cell surface proteins implicated in physiological antigenic signaling.
Demonstration of Differential
CsA Enhances TGF-~3 Protein Production. CsA's ability to augment TGF-3 gene expression was evident at the level of production of functionally active TGFq3 protein. As illustrated in Fig. 3 , the highest levels of TGF-3 protein were found in the supernatants of T cells pretreated with CsA and then signaled with either DAG and ionomycin or with cross- Figure 1 . Design and authentication of the TGF-3 competitor DNA construct. The primer design, the restriction site for MseI, the subfragments generated by Msel digestion of the TGF-/3 PCR product, the insert DNA, and the creation of the competitor DNA construct are all schematically shown in A. Agarose gel dectrophoretic validation of the 246-bp TGF-~ PCR product, generation of the appropriate sized subfragraents of 210 and 36 bp lengths after digestion with MseI, the insert DNA of 44 bp, and the 290-bp competitor DNA construct are shown in B. The digestion with MseI of the 290-bp TGF-3 competitor DNA construct yielding subfragments of 210, 44 and 36 bp and the 123-bp and the pGEM ladders are also shown in B. " Highly purified T cells (106 cells/ml) were incubated with the agents shown for 1, 4, 16, or 40 h. Total KNA was then isolated, reverse transcribed into cDNA, and amplified by PCR. The amount of TGF-~ mRNA was quantified by using the 290-bp TGF-B competitor DNA construct and the IL-2 mRNA with the 178-bp IL-2 competitor DNA construct in the competitive PCR. DAG, 10.0 #g/ml; ionomycin, 1.0 #M; CsA, 100 ng/ml.
linked anti-CD2 and anti-CD3 mAbs. The bioactivity (growth inhibition of mink lung epithelial cells) was best observed after acidification of the T cell supernatants and was inhibited, in each instance, by an avian anti-TGF-/3 antibody (Fig. 3 B) .
Conclusions and Implications. TGF-/3, a potent inhibitor of T cell growth and differentiation, is considered also as a fibrogenic cytokine (1, 2) . Our observation that CsA enhances TGF-B gene expression, thus, suggests a novel and unifying mechanism for the immunosuppression as well as for the renal fibrosis encountered with CsA usage. Our investigation also suggests a new hypothesis for the CsA-mediated inhibition of new DNA synthesis by T cells (since TGF-/3 inhibits c-myc gene expression and c-myc expression contributes to T-cell growth [9] ) and for the CsA-associated vasoconstriction and hypertension (since TGF-~/enhances the expression of the potent vasoconstrictor, endothelin [10] ).
CsA has selective inhibitory effects on the appearance of DNA regulatory proteins (11) . Thus, prevention by CsA of The effect of 12.5/zg of neutralizing anti-TGF-/9 antibody on purified 500 pg/ml TGF-B (control) or on the TGF-/9 bioactivity found in the supernatants ofT cells stimulated in the presence of 100 ng/ml of CsA.
the emergence of nuclear regulatory factors that bind to the negative regulatory sequence of the TGF-/~ gene or the lack of inhibition by CsA of DNA regulatory proteins that promote TGF-/9 gene expression might be responsible for our results. These hypotheses as well as whether CsA differentially regulates TGF-B and Ib2 gene expression in vivo are to be explored in our future studies.
